Joseph Piepmeier, MD, FAANS
Nixdorff-German Professor Emeritus of NeurosurgeryDownloadHi-Res Photo
Cards
Appointments
Neurosurgery
Primary
Contact Info
Neurosurgery
PO Box 208082
New Haven, CT 06520-8082
United States
About
Copy Link
Titles
Nixdorff-German Professor Emeritus of Neurosurgery
Biography
Dr. Joseph M. Piepmeier serves as the Chief of the Section of Surgical Neuro-oncology and Vice-Chair for Clinical Affairs in the Department of Neurosurgery. He received his undergraduate degree from Duke University and his M.D. from the University of Tennessee School of Medicine. He completed his internship and residency training in neurosurgery at Yale University School of Medicine and joined the neurosurgery faculty in 1982. He is certified by the American Board of Neurological Surgery. The primary focus of Dr. Piepmeier's clinical and laboratory work is neuro-oncology.
Last Updated on September 01, 2024.
Appointments
Neurosurgery
EmeritusPrimary
Other Departments & Organizations
- Brain Tumor Center
- Developmental Therapeutics
- Gamma Knife Center
- Gamma Knife Radiosurgery
- Neurosurgery
- Yale Cancer Center
Education & Training
- MD
- University of Tennessee (1975)
Board Certifications
Neurological Surgery
- Certification Organization
- AB of Neurological Surgery
- Original Certification Date
- 1984
Research
Copy Link
Overview
Medical Research Interests
Biopsy, Needle; Brain Neoplasms; Diseases; Neoplasms; Nervous System Diseases; Neuroma, Acoustic; Neurosurgery
Research at a Glance
Yale Co-Authors
Frequent collaborators of Joseph Piepmeier's published research.
Publications Timeline
A big-picture view of Joseph Piepmeier's research output by year.
Research Interests
Research topics Joseph Piepmeier is interested in exploring.
Michael B. Bracken, PhD, MPH, FACE
Theodore Holford, PhD
Anita Huttner, MD
Jennifer Moliterno, MD, FAANS
Jiangbing Zhou, PhD
Murat Günel, MD, FACS, FAHA, FAANS
107Publications
11,383Citations
Brain Neoplasms
Neoplasms
Neurosurgery
Publications
2023
Imaging metabolism of deuterated glucose in patients with primary brain tumors
Corbin Z, Liu Y, Fulbright R, Thaw-Poon S, Baehring J, Blondin N, Kim P, Omuro A, Chiang V, Moliterno J, Omay S, Piepmeier J, Rothman D, de Graaf R, De Feyter H. Imaging metabolism of deuterated glucose in patients with primary brain tumors. Proceedings Of The International Society For Magnetic Resonance In Medicine ... Scientific Meeting And Exhibition. 2023 DOI: 10.58530/2023/0142.Peer-Reviewed Original Research
2020
Primary melanotic tumors of the nervous system: a consecutive case series
Grosshans H, Huttner A, Piepmeier J, Kaulen L, Fulbright R, Baehring J, Karschnia P. Primary melanotic tumors of the nervous system: a consecutive case series. European Journal Of Neurology 2020, 27: 2303-2307. PMID: 32654331, DOI: 10.1111/ene.14437.Peer-Reviewed Original ResearchCitationsAltmetricMeSH Keywords and ConceptsConceptsPrimary melanotic tumorsNervous systemRelapsed diseaseClinical presentationMelanotic lesionsFavorable outcomeRadiation therapyPre-contrast T1-weighted imagingRelative incidenceMelanotic tumorsHomogenous contrast enhancementYale Cancer CenterAggressive surgical treatmentConsecutive case seriesPsammomatous melanotic schwannomaNervous system tumorsT1-weighted imagingT2-weighted imagingTumor mass effectMagnetic resonance imagingMelanin-containing cellsS100 positivitySurgical resectionSurgical treatmentTumor Registry
2019
Leptomeningeal dissemination of low-grade neuroepithelial CNS tumors in adults: a 15-year experience
Karschnia P, Barbiero FJ, Schwaiblmair MH, Kaulen LD, Piepmeier JM, Huttner AJ, Becker KP, Fulbright RK, Baehring JM. Leptomeningeal dissemination of low-grade neuroepithelial CNS tumors in adults: a 15-year experience. Neuro-Oncology Practice 2019, 7: 118-126. PMID: 32257290, PMCID: PMC7104875, DOI: 10.1093/nop/npz020.Peer-Reviewed Original ResearchCitationsConceptsLeptomeningeal disseminationRare complicationCNS tumorsInitial tumor diagnosisMedian overall survivalYale Cancer CenterPredictors of outcomeMean time intervalAggressive treatmentOverall survivalSystemic therapyConsecutive patientsSystemic treatmentTumor depositsClinical presentationCancer CenterHistopathological diagnosisHistological entityClinical signsTimely diagnosisNeuro-oncologyTumor spectrumEarly symptomsVariable enhancementRelative incidence
2016
Recurrent somatic mutations in POLR2A define a distinct subset of meningiomas
Clark VE, Harmancı AS, Bai H, Youngblood MW, Lee TI, Baranoski JF, Ercan-Sencicek AG, Abraham BJ, Weintraub AS, Hnisz D, Simon M, Krischek B, Erson-Omay EZ, Henegariu O, Carrión-Grant G, Mishra-Gorur K, Durán D, Goldmann JE, Schramm J, Goldbrunner R, Piepmeier JM, Vortmeyer AO, Günel JM, Bilgüvar K, Yasuno K, Young RA, Günel M. Recurrent somatic mutations in POLR2A define a distinct subset of meningiomas. Nature Genetics 2016, 48: 1253-1259. PMID: 27548314, PMCID: PMC5114141, DOI: 10.1038/ng.3651.Commentaries, Editorials and LettersCitationsAltmetricMeSH KeywordsCatalytic DomainChromosomes, Human, Pair 22Cohort StudiesDNA Mutational AnalysisEnhancer Elements, GeneticExomeGene Expression Regulation, NeoplasticGenotypeHumansKruppel-Like Factor 4Kruppel-Like Transcription FactorsMeningeal NeoplasmsMeningiomaMutationNeurofibromin 2RNA Polymerase IITumor Necrosis Factor Receptor-Associated Peptides and ProteinsIncreased Nanoparticle Delivery to Brain Tumors by Autocatalytic Priming for Improved Treatment and Imaging
Han L, Kong DK, Zheng MQ, Murikinati S, Ma C, Yuan P, Li L, Tian D, Cai Q, Ye C, Holden D, Park JH, Gao X, Thomas JL, Grutzendler J, Carson RE, Huang Y, Piepmeier JM, Zhou J. Increased Nanoparticle Delivery to Brain Tumors by Autocatalytic Priming for Improved Treatment and Imaging. ACS Nano 2016, 10: 4209-4218. PMID: 26967254, PMCID: PMC5257033, DOI: 10.1021/acsnano.5b07573.Peer-Reviewed Original ResearchCitationsAltmetricMeSH Keywords and ConceptsMeSH KeywordsAnimalsAntineoplastic AgentsBiological TransportBlood-Brain BarrierBrain NeoplasmsCell Line, TumorDecanoic AcidsDrug Delivery SystemsEthanolaminesFemaleGenetic TherapyHeterograftsHumansMatrix Metalloproteinase 2MiceMice, Inbred C57BLNanoparticlesOptical ImagingPaclitaxelPermeabilityPolymersPurinesPyrazolesScorpion VenomsTranscytosisTumor MicroenvironmentConceptsBlood-brain barrierLow delivery efficiencyTransport of nanoparticlesCancer gene therapyNanoparticle deliveryMore nanoparticlesBrain tumorsNanoparticlesDelivery efficiencyGene therapySystemic deliveryNPsBrain malignanciesBBB modulatorsPharmacological agentsBrain cancerBrain regionsTumorsDeliveryBrainImproved treatmentInadequate amountsPositive feedback loopChemotherapyMalignancy
2014
Imaging the delivery of brain-penetrating PLGA nanoparticles in the brain using magnetic resonance
Strohbehn G, Coman D, Han L, Ragheb RR, Fahmy TM, Huttner AJ, Hyder F, Piepmeier JM, Saltzman WM, Zhou J. Imaging the delivery of brain-penetrating PLGA nanoparticles in the brain using magnetic resonance. Journal Of Neuro-Oncology 2014, 121: 441-449. PMID: 25403507, PMCID: PMC4323763, DOI: 10.1007/s11060-014-1658-0.Peer-Reviewed Original ResearchCitationsAltmetricMeSH Keywords and ConceptsMeSH KeywordsAnimalsAntineoplastic AgentsBrain NeoplasmsConvectionDrug Delivery SystemsFerric CompoundsGlioblastomaHumansImage Processing, Computer-AssistedLactic AcidMagnetic Resonance ImagingNanoparticlesNeuroimagingPolyglycolic AcidPolylactic Acid-Polyglycolic Acid CopolymerRatsRats, Sprague-DawleyConceptsBrain-penetrating nanoparticlesSuperparamagnetic iron oxideEfficient deliveryDrug-loaded nanoparticlesDistribution of nanoparticlesTransverse relaxivityPLGA nanoparticlesNanoparticlesConvection-enhanced deliveryDelivery platformFuture clinical applicationsUniversal tumor recurrenceClinical translationSignal attenuationDetection modalitiesIron oxideSame morphologyParticle distributionDeliveryGroundbreaking approachClinical applicationRelevant volumesRelaxivityTreatment of GBMOxide
2013
Highly penetrative, drug-loaded nanocarriers improve treatment of glioblastoma
Zhou J, Patel TR, Sirianni RW, Strohbehn G, Zheng MQ, Duong N, Schafbauer T, Huttner AJ, Huang Y, Carson RE, Zhang Y, Sullivan DJ, Piepmeier JM, Saltzman WM. Highly penetrative, drug-loaded nanocarriers improve treatment of glioblastoma. Proceedings Of The National Academy Of Sciences Of The United States Of America 2013, 110: 11751-11756. PMID: 23818631, PMCID: PMC3718184, DOI: 10.1073/pnas.1304504110.Peer-Reviewed Original ResearchCitationsAltmetricMeSH Keywords and ConceptsClinical Presentation in Diffuse Low-Grade Gliomas
Torres-Reveron J, Piepmeier J, Becker K. Clinical Presentation in Diffuse Low-Grade Gliomas. 2013, 179-188. DOI: 10.1007/978-1-4471-2213-5_12.Peer-Reviewed Original ResearchCitationsConceptsDiffuse low-grade gliomasLow-grade gliomasCommon presenting symptomHigh-grade lesionsPrimary brain tumorsStandard imaging modalityPresenting symptomHistopathological findingsClinical presentationTumor sizeNeurological syndromeAnaplastic transformationBrain tumorsMultimodal evaluationConventional imaging technologiesImaging modalitiesActive investigationTumorsGliomasNew advancesSeizuresSyndromeLesionsSymptomsGenomic Analysis of Non-NF2 Meningiomas Reveals Mutations in TRAF7, KLF4, AKT1, and SMO
Clark VE, Erson-Omay EZ, Serin A, Yin J, Cotney J, Özduman K, Avşar T, Li J, Murray PB, Henegariu O, Yilmaz S, Günel JM, Carrión-Grant G, Yılmaz B, Grady C, Tanrıkulu B, Bakırcıoğlu M, Kaymakçalan H, Caglayan AO, Sencar L, Ceyhun E, Atik AF, Bayri Y, Bai H, Kolb LE, Hebert RM, Omay SB, Mishra-Gorur K, Choi M, Overton JD, Holland EC, Mane S, State MW, Bilgüvar K, Baehring JM, Gutin PH, Piepmeier JM, Vortmeyer A, Brennan CW, Pamir MN, Kılıç T, Lifton RP, Noonan JP, Yasuno K, Günel M. Genomic Analysis of Non-NF2 Meningiomas Reveals Mutations in TRAF7, KLF4, AKT1, and SMO. Science 2013, 339: 1077-1080. PMID: 23348505, PMCID: PMC4808587, DOI: 10.1126/science.1233009.Peer-Reviewed Original ResearchCitationsAltmetricMeSH Keywords and ConceptsMeSH KeywordsAdultAgedAged, 80 and overBrain NeoplasmsChromosomes, Human, Pair 22DNA Mutational AnalysisFemaleGenes, Neurofibromatosis 2Genomic InstabilityGenomicsHumansKruppel-Like Factor 4Kruppel-Like Transcription FactorsMaleMeningeal NeoplasmsMeningiomaMiddle AgedMutationNeoplasm GradingProto-Oncogene Proteins c-aktReceptors, G-Protein-CoupledSmoothened ReceptorTumor Necrosis Factor Receptor-Associated Peptides and Proteins
2012
Low-Grade Gliomas When and How to Treat
Omay SB, Piepmeier JM, Knisely JP. Low-Grade Gliomas When and How to Treat. Hematology/Oncology Clinics Of North America 2012, 26: 797-809. PMID: 22794284, DOI: 10.1016/j.hoc.2012.05.001.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsCitationsMeSH Keywords and ConceptsConceptsSurgical resectionLow-grade gliomasPatient-specific variablesSame imaging techniqueRadiotherapeutic managementUncommon tumorClinical trialsOperative techniqueHistopathologic characterizationGrade gliomasOptimal managementAdditional studiesGliomasResectionAdequate samplesImaging techniquesPatientsPrognosisManagementTumorsTrials
Academic Achievements & Community Involvement
Copy Link
Activities
activity B*CURED Foundation
2008 - PresentCommitteesMemberDetailsMedical Advisory Boardactivity AANS
2009 - PresentCommitteesMemberDetailsEmerging Technology Committeeactivity YNHH
2007 - 2010CommitteesMemberDetailsSmilow Cancer Hospital Campaignactivity Goldhirsch Foundation
2002 - 2005CommitteesMemberDetailsScientific review committee
Honors
honor Connecticut Magazine Top Docs 2016
04/01/2016Regional AwardConnecticut MagazineDetailsUnited Stateshonor Connecticut Magazine Top Docs 2015
04/03/2015Regional AwardConnecticut MagazineDetailsUnited Stateshonor Altman Memorial Lecture
01/01/2008UnknownU PennDetailsUnited Stateshonor President
01/01/2008, 01/01/2007National AwardNeurosurgical Society of AmericaDetailsUnited Stateshonor Bittner Award Lecture AANS
01/01/2007UnknownDetailsUnited States
Links
Copy Link
Media
Get In Touch
Copy Link
Contacts
Appointment Number
Clinic Fax Number
Mailing Address
Neurosurgery
PO Box 208082
New Haven, CT 06520-8082
United States